Drugs / OSI-027
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04994002 | Sep 2021 → Jun 2022 | lymphatic malformation | Avalo Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00698243 | Jun 2008 → Feb 2013 | — | Astellas Pharma Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-08-04 | Avalo Therapeutics, Inc. | Regulatory Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations August 04, 2020 7:00am EDT avalotx.com ↗
Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation (RPDD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM). |
| 2020-08-03 | Avalo Therapeutics, Inc. | Regulatory Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations August 03, 2020 7:00am EDT avalotx.com ↗
Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-08-04 | Avalo Therapeutics, Inc. | Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations August 04, 2020 7:00am EDT avalotx.com ↗ |
| 2020-08-03 | Avalo Therapeutics, Inc. | Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations August 03, 2020 7:00am EDT avalotx.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSI-027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698243 ↗ |
| Known as | AEVI-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3120215 ↗ |
| Known as | ASP 7486 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3120215 ↗ |
| Known as | CERC-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04994002 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3120215 ↗ |
| Modality | Small molecule | — CHEMBL3120215 ↗ |
| Route | Oral | “Administered orally” NCT00698243 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3120215 ↗ |